BioCryst Pharmaceuticals, Inc. (BCRX) NASDAQ
8.76
-0.25(-2.77%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.76
-0.25(-2.77%)
Currency In USD
| Previous Close | 9.01 |
| Open | 9.02 |
| Day High | 9.12 |
| Day Low | 8.7 |
| 52-Week High | 11.31 |
| 52-Week Low | 6 |
| Volume | 2.31M |
| Average Volume | 5.31M |
| Market Cap | 1.84B |
| PE | 7.24 |
| EPS | 1.21 |
| Moving Average 50 Days | 8.71 |
| Moving Average 200 Days | 7.87 |
| Change | -0.25 |
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
GlobeNewswire Inc.
Feb 11, 2026 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy o
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
GlobeNewswire Inc.
Feb 05, 2026 12:01 PM GMT
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026. BioCryst managemen
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
GlobeNewswire Inc.
Jan 23, 2026 2:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transacti